



Immune Checkpoints and Autoimmunity

Guest Editor:

Dr. Stefania Croci

Clinical Immunology, Allergy and
Advanced Biotechnologies Unit,
Azienda USL-IRCCS di Reggio
Emilia, 42123 Reggio Emilia, Italy

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editor

Immune checkpoint molecules have emerged as key regulators of the immune system. They are crucial for self-tolerance but also for the activation of the immune system. To date, most studies have investigated the role of immune checkpoints in cancers, while fewer data are available in autoimmune and inflammatory diseases. Upregulation of inhibitory checkpoint molecules by cancer cells or in the tumor microenvironment can favor cancer cell escape from immune surveillance. Drugs which are able to block the inhibitory checkpoint molecules have shown efficacy in some types of cancers. On the other hand, they are sometimes coupled with the onset of immune-mediated reactions. Once the role of immune checkpoints in autoimmune and inflammatory diseases is defined, drugs and approaches able to modulate such molecules can be used for therapy.

We invite authors to submit original research (basic, translational, and clinical research) and review articles about the deregulation, biological functions, and therapeutic potential of immune checkpoints in autoimmune and inflammatory diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shaker A. Mousa

1. The Pharmaceutical Research
Institute, Albany College of
Pharmacy and Health Sciences, 1
Discovery Drive (Room 238),
Rensselaer, NY 12144, USA
2. Vascular Vision
Pharmaceuticals Co., Rensselaer
Polytechnic Park, Troy, NY 12180
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: [JCR - Q1 \(Pharmacology & Pharmacy\)](#) / [CiteScore - Q2 \(Medicine \(miscellaneous\)\)](#)

Contact Us

Biomedicines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[@Biomed_MDPI](https://twitter.com/Biomed_MDPI)